Navigation Links
Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
Date:6/15/2010

JERUSALEM, June 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that results of two of its clinical trials will be presented by Chief Scientific Officer Dr. Miriam Kidron, at the forthcoming 70th Annual Scientific Sessions of the American Diabetes Association, to be held in Orlando, Florida. The first abstract, entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration" examines exposure of Type 1 diabetes patients to Oramed's oral insulin. The second abstract, entitled "A Single-Blind, Two-period Study to Assess the Safety and Pharmacodynamics of an Orally Delivered GLP-1 Analog (Exenatide) in Healthy Subjects" details a first-in-human study with Oramed's oral GLP-1 Analog.

The posters will be presented on June 28, 2010 at 12:00 PM - 2:00 PM in the Poster Hall. The posters will also be printed in the Scientific Sessions Abstract book which is the June 2010 supplement for the Journal Diabetes. The posters will be displayed throughout the conference for viewing in the Poster Hall.

The poster entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration" will be featured in a guided tour in the Poster Hall. The tour title is "Innovations in Novel Insulin Preparations" and is scheduled for Monday June 28 at

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
10. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
11. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, 2014 ... and unforgiving environments. Human exploration of space requires astronauts ... ensure mission safety and success, and prevent potential errors ... mission success, little is known about how cognition is ... are primarily affected. Now, Penn Medicine researchers ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 On January, ... the Baltimore and Washington D.C. science community to the ... The event, sponsored by the Protein Society, will take ... University Center, Room 312. Through discussion, presentations and ... structural importance of proteins, their role in the industry ...
(Date:11/26/2014)... NC (PRWEB) November 26, 2014 PMG ... Advisory Board. PMG Research is a network of sites that ... access to over 2 million patient lives through its partnerships ... is comprised of 11 hub site locations in the Southeastern ... The first term of the board will be ...
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... 27 Craneware , Inc. (AIM: ... U.S. healthcare, today announced a presentation at the Healthcare ... for November 5-7 in Chicago, IL. The session will ... 30 years experience - Director of Revenue Integrity, Wendi ...
... Oct. 27 Precision Antibody(TM) has been selected as ... Cancer Institute (NCI),s Clinical Proteomic Technologies for Cancer (CPTC), ... the quality of monoclonal antibody reagents available for clinical ... of a third solicitation for contract proposals from custom ...
... 27 Syngenta Ventures announced today that it has ... biotechnology company focused on the use of metabolomics in ... by Syngenta Ventures, Syngenta,s newly-established corporate venture capital subsidiary. ... in-house R&D work and enables us to be even ...
Cached Biology Technology:Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 2Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 3Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3Syngenta Ventures Invests in U.S. Biotech Company Metabolon 2Syngenta Ventures Invests in U.S. Biotech Company Metabolon 3
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... is a leading cause of mortality worldwide, accounting for more ... is expected to exceed 12 million. The ESMO Congress provides ... on the treatment of cancer Congress Program Highlights ... trials, potentially practice changing, Promising new drugs to treat ovarian, ...
... the microscope, the bacteria start dividing normally, two cells become ... cells begin "popping," like circus balloons being struck by darts. ... captured it on video, turns out to be an example ... scientists creating living, synthetic circuits out of bacteria. Even when ...
... CHICAGO The American Dietetic Association has published an ... in schools that calls on schools and communities to ... all children and to promote educational environments that help ... lives. ADA,s updated position paper, published in the ...
Cached Biology News:35th ESMO Congress media alert 235th ESMO Congress media alert 3Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3Schools, communities share responsibility for child nutrition 2Schools, communities share responsibility for child nutrition 3
... to be able to handle larger sample volumes, ... well as interface with telemetry systems. The ... with dogs, pigs, and primates. The system ... and the computer can be located outside the ...
... laboratories working in a regulated environment, ... pipette calibration software that automates gravimetric ... a framework that meets todays regulatory ... a secure solution that includes a ...
... in plasma from juvenile or male fish is ... chemicals (EDCs) with estrogenic effects in fish. Quantification ... for the estrogenic effects of EDCs in fish. ... double-antibody immunometric (sandwich) EIA for analyzing Vtg in ...
... target for which no antibody exists? Having difficulty ... for a variety of pharmaceutical, biotech and academic ... our technology and expertise in antibody generation to ... patented RabMAb development technology , High affinity and ...
Biology Products: